YMYong Ma

Yong Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yong Ma has a total of 112 co-authors. Here are the top co-authors by number of shared publications:

  • Donglu Zhang

    Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California

    7 shared publications
  • Thomas H. Pillow

    Drug Metabolism and Disposition (Y.M., S.C.K., D.Z.), Biochemical and Cellular Pharmacology (J.D.C.-C.), and Discovery Chemistry (P.S.D., T.H.P.), Genentech, South San Francisco, California

    5 shared publications
  • Josefa Dela Cruz-Chuh

    Drug Metabolism and Disposition (Y.M., S.C.K., D.Z.), Biochemical and Cellular Pharmacology (J.D.C.-C.), and Discovery Chemistry (P.S.D., T.H.P.), Genentech, South San Francisco, California

    4 shared publications
  • Ming Hu

    Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, USA

    4 shared publications
  • Peter S. Dragovich

    Drug Metabolism and Disposition (Y.M., S.C.K., D.Z.), Biochemical and Cellular Pharmacology (J.D.C.-C.), and Discovery Chemistry (P.S.D., T.H.P.), Genentech, South San Francisco, California

    4 shared publications
  • S. Cyrus Khojasteh

    Drug Metabolism and Disposition (Y.M., S.C.K., D.Z.), Biochemical and Cellular Pharmacology (J.D.C.-C.), and Discovery Chemistry (P.S.D., T.H.P.), Genentech, South San Francisco, California

    4 shared publications

Latest Publications

  • Discovery, Evolution, and Applications of Mass Defect Filtering in Drug Metabolite Identification

    by Panjing Zhang, Kevin Johnson, Yong Ma, Jiang Zheng, S.CYrus Khojasteh, Donglu Zhang

  • Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates In Vivo Antitumor Activity

    by Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, John T. P. Chiang, Clarissa C. Lee, Weiqun Li, Susanne Steggerda, Ethan Emberley, Matthew Gross, et al.

    CD73 (ecto-5'-nucleotidase) has emerged as an attractive target for cancer immunotherapy of many cancers. CD73 catalyzes the hydrolysis of adenosine monophosphate (AMP) into highly immunosuppressive adenosine that plays a critical role in tumor progression. Herein, we report our efforts in developing orally bioavailable and highly potent small-molecule CD73 inhibitors from the reported hit molecule 2 to lead molecule 20 and then finally to compound 49. Compound 49 was able to reverse AMP-mediated suppression of CD8+ T cells and completely inhibited CD73 activity in serum samples from various cancer patients. In preclinical in vivo studies, orally administered 49 showed a robust dose-dependent pharmacokinetic/pharmacodynamic (PK/PD) relationship that correlated with efficacy. Compound 49 also demonstrated the expected immune-mediated antitumor mechanism of action and was efficacious upon oral administration not only as a single agent but also in combination with either chemotherapeutics or checkpoint inhibitor in the mouse tumor model.


  • Open Access

    Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes

    by Yong Ma, Josefa Dela Cruz-Chuh, S. Cyrus Khojasteh, Peter S. Dragovich, Thomas H. Pillow, Donglu Zhang

    Carfilzomib (CFZ) is a proteasome inhibitor used for oncology indication such as treating multiple myeloma. CFZ is a potent cytotoxic agent with an IC50 in nanomolar range in various cancer cell lines and was considered as a potential payload for antibody drug conjugates (ADCs). However, the conjugated CFZ to anti-CD22 or anti-HER2 antibody totally abolishes the in vitro potency. This was a surprise since with other payload such as monomethyl auristatin E (MMAE) where a potent anti-proliferation efficacy was retained as MMAE alone or as a payload in an ADC. Further investigations were conducted using CFZ alone, CFZ with a linker and CFZ-ADC with tissue matrices including lysosomal enzymes. With CFZ linked to the ADC, cathepsin B (lysosomal enzyme) was efficient in liberating CFZ from the ADC by cleavage of valine-citrulline linker. At the same time, the liberated CFZ in the lysosome was inactivated by further metabolism by lysosomal enzymes. The metabolic profiles demonstrated that the products from epoxide and amide hydrolysis were identified from these incubations. These results suggested that the CFZ-ADC upon uptake and internalization specifically delivers CFZ payload to the lysosomes, where the CFZ was inactivated. On the other hand, CFZ by itself is not as vulnerable and could reach its target. Therefore, the lysosomal stability is an important criterion in the selection of a payload for making next generation of potent ADC therapeutics. SIGNIFICANCE STATEMENT N/A


  • Metabolism of Phenolic Compounds in LPS-stimulated Raw264.7 Cells Can Impact Their Anti-inflammatory efficacy: Indication of Hesperetin

    by Yong Ma, Yu He, Taijun Yin, Haoqing Chen, Song Gao, Ming Hu

    Raw264.7 is a murine macrophage-like cell line commonly used to study the anti-inflammatory efficacy of natural compounds. However, the impacts of long-time incubation on the tested compounds are often inappropriately ignored. Among 77 natural phenolic compounds (mainly flavonoids), only 36 remain more than 70% after a 15-h incubation in cell culture medium at 37 °C. Interestingly, for those compounds with a relatively good chemical stability, the presence of Raw264.7 cells could accelerate their disappearance in the medium, indicating that cellular metabolism occurred. As a representative phenolic, hesperetin was found to be efficiently metabolized by Raw264.7 cells and the metabolite was identified as a glucuronide in the further investigation. The glucuronidation activity is constitutive in this cell line. At certain concentration levels of hesperetin, the ability of hesperetin to inhibit PGD2 production in LPS-induced Raw264.7 cells was significantly enhanced by introducing β-glucuronidase, which can hydrolyze hesperetin glucuronide, into the incubation medium. The results indicate that glucuronidation and excretion of hesperetin can significantly impact its bioactivity in Raw264.7 cells.


  • Modulating Antibody–Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification

    by Dian Su, Katherine R. Kozak, Jack Sadowsky, Shang-Fan Yu, Aimee Fourie-O’donohue, Christopher Nelson, Richard Vandlen, Rachana Ohri, Luna Liu, Carl Ng, et al.

    Previous investigations on antibody-drug conjugate (ADC) stability have focused on drug release by linker-deconjugation due to the relatively stable payloads such as maytansines. Recent development of ADCs has been focused on exploring technologies to produce homogeneous ADCs and new classes of payloads to expand the mechanisms of action of the delivered drugs. Certain new ADC payloads could undergo metabolism in circulation while attached to antibodies and thus affect ADC stability, pharmacokinetics, and efficacy and toxicity profiles. Herein, we investigate payload stability specifically and seek general guidelines to address payload metabolism and therefore increase the overall ADC stability. Investigation was performed on various payloads with different functionalities (e.g., PNU-159682 analog, tubulysin, cryptophycin, and taxoid) using different conjugation sites (HC-A118C, LC-K149C, and HC-A140C) on THIOMAB antibodies. We were able to reduce metabolism and inactivation of a broad range of payloads of THIOMAB antibody-drug conjugates by employing optimal conjugation sites (LC-K149C and HC-A140C). Additionally, further payload stability was achieved by optimizing the linkers. Coupling relatively stable sites with optimized linkers provided optimal stability and reduction of payloads metabolism in circulation in vivo.


  • Immolation of p-Aminobenzyl Ether Linker and Payload Potency and Stability Determine the Cell-Killing Activity of Antibody–Drug Conjugates with Phenol-Containing Payloads

    by Donglu Zhang, Hoa Le, Josefa Dela Cruz-Chuh, Sudheer Bobba, Jun Guo, Leanna Staben, Chenghong Zhang, Yong Ma, Katherine R. Kozak, Gail D. Lewis Phillips, et al.

    The valine-citrulline (Val-Cit) dipeptide and p-aminobenzyl (PAB) spacer have been commonly used as a cleavable self-immolating linker in ADC design including in the clinically approved ADC, brentuximab vedotin (Adcetris). When the same linker was used to connect to the phenol of the cyclopropabenzindolone (CBI) (P1), the resulting ADC1 showed loss of potency in CD22 target-expressing cancer cell lines (e.g., BJAB, WSU-DLCL2). In comparison, the conjugate (ADC2) of a cyclopropapyrroloindolone (CPI) (P2) was potent despite the two corresponding free drugs having similar picomolar cell-killing activity. Although the corresponding spirocyclization products of P1 and P2, responsible for DNA alkylation, are a prominent component in buffer, the linker immolation was slow when the PAB was connected as an ether (PABE) to the phenol in P1 compared to that in P2. Additional immolation studies with two other PABE-linked substituted phenol compounds showed that electron-withdrawing groups accelerated the immolation to release an acidic phenol-containing payload (to delocalize the negative charge on the anticipated anionic phenol oxygen during immolation). In contrast, efficient immolation of LD4 did not result in an active ADC4 because the payload (P4) had a low potency to kill cells. In addition, nonimmolation of LD5 did not affect the cell-killing potency of its ADC5 since immolation is not required for DNA alkylation by the center-linked pyrrolobenzodiazepine. Therefore, careful evaluation needs to be conducted when the Val-Cit-PAB linker is used to connect antibodies to a phenol-containing drug as the linker immolation, as well as payload potency and stability, affects the cell-killing activity of an ADC.


  • Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8)

    by Yong Ma, Yue Fu, S. Cyrus Khojasteh, Deepak Dalvie, Donglu Zhang

    Glucuronidation is in general considered as a terminal metabolic step that leads to direct elimination of drugs and generally abolishes their biological activity. However, there is growing evidence to suggest that glucuronides can be ligands of human CYP2C8, making CYP2C8 distinct from the other CYP isoforms. Several classes of glucuronide conjugates, which include acyl glucuronides, ether glucuronides, N-glucuronides, and carbamoyl glucuronides, have been shown to be substrates or time-dependent inhibitors of CYP2C8. Although the structures of CYP2C8-glucuronide complexes have not been determined, the structural features of CYP2C8 active site support its binding to anionic and bulky ligands like glucuronides. As interaction perpetrators with CYP2C8, glucuronides of gemfibrozil and clopidogrel showed marked clinical drug–drug interactions (e.g., with cerivastatin and repaglinide), which are more than expected from the parent drug. This review summarizes glucuronides as CYP2C8 ligands and the active-site structural features of CYP2C8 that allow potential binding to glucuronides.


  • Intermediates Stabilized by Tris(triazolylmethyl)amines in the CuAAC Reaction

    by Haoqing Chen, Chengzhi Cai, Siheng Li, Yong Ma, Sijin Luozhong, Zhiling Zhu

    Tris(triazolylmethyl)amine ligands (TL) are widely used to accelerate the CuI‐catalyzed azide‐alkyne cycloaddition (CuAAC) reaction, but its mechanistic role remains unclear. Using electrospray ionization mass spectrometry, we detected for the first time the trinuclear TL‐CuI3‐acetylide and the dinuclear TL‐CuI2‐acetylide complexes in aqueous solution. The apparent second‐order rate constants of their reaction with an azide were 27 and 783 m−1⋅s−1 when the alkyne was tethered to TL. In the catalytic system without the tether, the rate constant increased to >146 m−1⋅s−1 for the TL‐CuI3‐acetylide, but dropped about 14‐fold to approximately 55 m−1⋅s−1 for the TL‐CuI2‐acetylide. The results indicated that TL accelerated the reaction by stabilizing the CuI2‐ and CuI3‐acetylide and their azide‐adduct intermediates, but this role is largely weakened by excess alkyne and other competing ligands under catalytic conditions.